Living Kidney Donors Undergoing VAMS-nephrectomy
Conditions
Brief summary
Hyperalgesia is known to be caused by the excitatory amino acid through NMDA receptor. GABA, an inhibitory amino acid, alters the opioid receptor sensitivity against pain resulting hyperalgesia. If the GABA level can be maintained at certain level, the progression into hyperalgesia can be averted. GABA related drugs are known to decrease the postoperative opioid consumption, lower the degree of pain, and prevent hyperalgesia. We hypothesize the effective postoperative pain management and the prevention of hyperalgesia from pregabalin, GABA analogue, and the possible sex difference in such effects of pregabalin.
Interventions
DRUGPregabalin_male
Pregabalin 150mg bid 1day Men
DRUGPregabalin_female
Pregabalin 150mg bid 1day Women
DRUGPlacebo_Men
Placebo durg
DRUGPlacebo_Women
Placebo\_Women
Sponsors
Yonsei University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
19 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* 18, \<51 years * healthy patients accepted for video-assisted living donor nephrectomy
Exclusion criteria
* Female patients who are pregnant or menopause * Patients undergoing hormonal therapy * Patients having neurologic disease or already taking GABA related drugs (pregabalin, gabapentin), or taking opioid drugs * Insulin resistant diabetes * Renal deficiency (eGFR \< 60 ml/min/1.73 m2) * Emergency operation, hemodynamically unstable patients * Foreigner * allergic to medication given in this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mechanical threshold | from 1 day before op to postop 48 hr | Mechanical threshold can be measured using von Frey filaments at both incision site and non-dominant arm |
Countries
South Korea
Outcome results
None listed